Accurate de novo design of hyperstable constrained peptides
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - …, 2016 - scholars.northwestern.edu
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
[引用][C] Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - Nature, 2016 - cir.nii.ac.jp
Accurate de novo design of hyperstable constrained peptides | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
[HTML][HTML] Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - Nature, 2016 - ncbi.nlm.nih.gov
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks
generally have shapes evolved to fit precisely into binding pockets on their targets. Such …
generally have shapes evolved to fit precisely into binding pockets on their targets. Such …
[PDF][PDF] Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - 2016 - academia.edu
The vast majority of drugs currently approved for use in humans are either proteins or small
molecules. Lying between the two in size, and integrating the advantages of both 1, 2 …
molecules. Lying between the two in size, and integrating the advantages of both 1, 2 …
Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - Nature, 2016 - go.gale.com
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - …, 2016 - ui.adsabs.harvard.edu
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - Nature (London), 2016 - osti.gov
Covalently-crosslinked peptides present attractive opportunities for developing new
therapeutics. Lying between small molecule and protein therapeutics in size, natural …
therapeutics. Lying between small molecule and protein therapeutics in size, natural …
Accurate de novo design of hyperstable constrained peptides
G Bhardwaj, VK Mulligan, CD Bahl, JM Gilmore… - Nature, 2016 - nyuscholars.nyu.edu
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks
generally have shapes that have evolved to fit precisely into binding pockets on their targets …
generally have shapes that have evolved to fit precisely into binding pockets on their targets …